Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE2635A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVE2635A | DRUG | - |
Inclusion Criteria: * Males or females 12 years or older; History of persistent bronchial asthma for at least 6 months; Documented use of an inhaled steroid for at least 1 month before screening; At screening, FEV1 40% or more of predicted normal and at randomization, FEV1 between 40 and 80% predic...
AVE2635A is an investigational small molecule being studied for the treatment of asthma. It is currently in Phase 2 clinical development. The drug is being evaluated in patients with persistent asthma to assess its efficacy and safety. AVE2635A is not yet approved and remains under clinical investigation.
The specific molecular target of AVE2635A has not been disclosed in available information. The drug is being studied for its potential role in treating asthma, but its mechanism of action is not publicly detailed. Further research and clinical data may clarify how AVE2635A works.
AVE2635A is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and efficacy in patients with asthma. The drug is currently in Phase 2 development.
AVE2635A is currently in Phase 2 clinical development for the treatment of asthma. It is an investigational drug and has not received regulatory approval. The Phase 2 trial has been completed, and the drug is not yet available for commercial use.
AVE2635A has one completed clinical trial registered under NCT00174746, titled 'Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma.' This Phase 2 study enrolled 1,145 participants with asthma in the United States. The trial was randomized, double-blind, and uncontrolled.
AVE2635A is associated with a clinical trial that studied inhaled ciclesonide, a glucocorticosteroid, in patients with persistent asthma. However, AVE2635A is the investigational drug name used in the trial. The relationship between AVE2635A and ciclesonide is not explicitly clarified in available data.